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The present study examines the eﬀects of divalent and trivalent Manganese (Mn2+/Mn3+) mixture inhalation on mice to obtain
a novel animal model of Parkinson disease (PD) inducing bilateral and progressive dopaminergic cell death, correlate those
alterations with motor disturbances, and determine whether l-DOPA treatment improves the behavior, to ensure that the
alterations are of dopaminergic origin. CD-1 male mice inhaled a mixture of Manganese chloride and Manganese acetate, one
hour twice a week for ﬁve months.Before Mn exposure, animalswere trained to perform motor function tests and were evaluated
each week after the exposure. By the end of Mn exposure, 10 mice were orally treated with 7.5mg/kg l-DOPA. After 5 months
of Mn mixture inhalation, striatal dopamine content decreased 71%, the SNc showed important reduction in the number of
TH-immunopositive neurons, mice developed akinesia, postural instability, and action tremor; these motor alterations were
reverted with l-DOPA treatment. Our data provide evidence that Mn2+/Mn3+ mixture inhalationproduces similarmorphological,
neurochemical, and behavioral alterations to those observed in PD providing a useful experimental model for the study of this
neurodegenerative disease.
1.Introduction
Parkinson disease (PD) is a progressive neurodegenerative
disorder that aﬀects 1% of the population over 55 years of
age. The pathologic hallmark of the disease is the loss of
dopaminergic neurons in the Substantia Nigra pars com-
pacta (SNc) and the presence of intracytoplasmic inclusions
named Lewy bodies, formed mainly by α-synuclein and
ubiquitin. In the striatum, there is a loss of dopamine (DA)
and its metabolites homovanillic acid and 3,4-dihydroxy-
phenylacetate [1–3]. The dopaminergic loss in the striatal
spiny neurons is followed by a cascade of events that ul-
timately changes its structure and the activity of basal
ganglia circuits, resulting in the development of PD symp-
tomatology. The main symptoms of the disease are tremor,
bradykinesia, hypokinesia, balance, and gait disturbances.
The basic process behind the nigrostriatal degeneration still
remains unsolved. However, among many other hypothet-
ical degenerative mechanisms, oxidative stress has become
an important candidate in producing the neuropathological
alterations in PD [3].
Although the etiology of PD is still not fully understood,
animal models have provided important clues. On the basis
of experimental and clinical ﬁndings, PD was the ﬁrst
neurological disease to be modeled and, subsequently, to
be treated by neurotransmitter replacement therapy [4]. All
PD models are based on the concept that parkinsonian
signs are related to dopaminergic nigral cell loss. Sev-
eral models exhibit many of the characteristic features of
the disease; however, none mimics the complex chronic
neurodegenerative features of human PD. The 6-hydrox-
ydopamine (6-OHDA) and the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) are neurotoxins which selec-
tivelyand rapidlydestroy catecholaminergicneurons(within
1–3 days), whereas in humans the PD pathogenesis follows a
progressive course over decades.
According to Emborg [5], an ideal animal model can be
described by presenting behavioral signs and pathology that2 Parkinson’s Disease
resemble the disease, including its time course. The closer
the similarity of a model is to PD, the higher the predictive
validity for clinical eﬃcacy is.
It has been investigated the eﬀects of Manganese (Mn) as
a PD model, due to its toxicity (referred to as manganism)
shares neurological symptoms with several clinical disorders
commonly described as “extrapyramidal motor system dys-
function,” and, in particular, idiopathic PD [6–8].
Postmortem studies in humans [9–13] and chronic stud-
i e si nn o n h u m a np r i m a t e s[ 14–18] and rodents [19–22]
revealed that Mn intoxication produces neuropathological
changes in the basal ganglia, structures that include the
globus pallidus (GP), caudate nucleus and putamen (stria-
tum), and less frequently the substantia nigra (SN) [12, 21,
23].
The humancentralnervoussystem isanimportant target
for Mn intoxication [6–8, 24–27]; its toxicity is targeted to
DA-rich brain regions neurons possibly via the dopamine
transporter (DAT) [28–31].
In vitro studies indicate that Mn produces an inhibition
of oxidative phosphorylation [32], increasing of reactive
oxygen species in synaptosomes [33], and enhances the rate
of DA auto-oxidation [34–36], while intrastriatal admin-
istration of Mn leads to impaired energy metabolism,
excitotoxic lesions, decreased DA, GABA, and substance P
levels [37, 38] and accelerate the oxidation of DA [36].
Moreover, it has been reported that unilateral intranigral
Mnadministration inducesipsilateralturning,whilebilateral
infusion resulted in akinesia and dystonic posturing of the
hind limbs, assuming that those alterations are due to
decreasing DA levels [38–40].
The cellular, intracellular, and molecular mechanisms
underlying neurotoxicity of Mn compounds are numerous,
as it impacts many biological activities depending on levels
androutesofexposure,dosage,ageoftheexposedindividual,
and duration of exposure [41].
Great discrepancy exists about Mn-inducing PD, includ-
ing the speciﬁcity of Mn-damaging GP or SN [7, 17, 42].
Olanow [43], Perl and Olanow [44], Lucchini et al. [45],
Guilarte [46], and others suggest that PD preferentially
damages DA neurons in the SN, while Mn preferentially
accumulates within and damages GP and striatum, while
sparing the nigrostriatal system. According to Calne et al.
[7], Lu et al. [47], Cersosimo and Koller [48], Aschner et
al. [49, 50], and others, the most important among these
diﬀerences is the lack of clinical response to l-DOPA.
However, studies have reported seemingly conﬂicting
results on the dopaminergic eﬀects of Mn (see Gwiazda et
al. [51]a n dG u i l a r t e[ 46] for review), including decrease
[14, 21, 27, 40, 52–56], increase [19, 57], both, increase
and decrease [20], or no change [25, 42, 58]i nn i g r a lo r
striatal DA concentrations in Mn-treated animals, possibly
reﬂecting eﬀects of the diﬀerent exposure regimens on DA
outcomes. These discrepancies may well reﬂect diﬀerences
in exposure route, magnitude, duration, Mn concentration
or compound, age of the experimental animals, and so
forth between studies, though they also demonstrate the
complexity of Mn toxicity and suggest that the factors
contributing to its toxicity are not well understood.
It seems that at lower doses, Mn increased DA and its
metabolite levels, while the opposite eﬀect was seen at higher
doses [20, 59]. Likewise, it has been suggested that higher
concentrations of Mn may signiﬁcantly accelerate the oxi-
dation of DA and other catecholamines, which concurrently
amplify the formation of reactive oxygen species [34, 36, 60].
It has been reported that divalent and trivalent man-
ganese may be transported into the brain across the blood-
brain and the blood-CSF barriers [61, 62]. Divalent Mn
can be transported into brain capillary endothelial cells
and choroidal epithelial cells via undeﬁned divalent metal
t r a n s p o r t e rD M T -1 ,D C T - 1 ,o rn r a m p - 2[ 63]. In the
brain, it is known that SN and striatum are regions rich
in DMT-1 [64]. On the other hand, trivalent Mn bound
to transferrin is transported across the brain barriers via
the receptor-mediated endocytosis [62]. Mn is then released
from the complex into the endothelial cell by endosomal
acidiﬁcation [50]. Mn released within the endothelial cells
is subsequently transferred to the abluminal cell surface for
release into the extracellular ﬂuid. Mn delivered to brain-
derived transferrin for extracellular transport, subsequently
is taken up by neurons, oligodendrocytes, and astrocytes
for usage and storage [65]. In the mitochondria, it has
been demonstrated that Mn inhibits complex I thereby
leading to altered oxidative phosphorylation, and it seems
that Mn3+ is more potent at inhibiting complex I than Mn2+
[66–68] and accelerates the oxidation of ferrous iron. Low
micromolar concentrations of Mn3+ are suﬃcient to trigger
an immediate oxidationofferrousiron, whereas divalentMn
at concentrations of 100-fold higher did not promote the
conversion of ferrous to ferric [69].
The enhanced ability of trivalent Mn to induce oxida-
tive stress has been conﬁrmed in rats given either man-
ganese chloride [MnCl2 (Mn2+)] or manganese acetate
[Mn(OAc)3 (Mn3+)] [67]; these authors report that MnCl2
(1–1000μM) produced dose-dependent increases of reactive
oxygenspeciesinstriatumwhereas MnOAcproducedsimilar
increases at much lower concentrations (1–100μM). Thus,
the valence of Mn and its metabolism seem to inﬂuence its
toxicity.
Therefore, the pro-oxidant activity of Mn2+ is dependent
on trace amounts of Mn3+, which may facilitate a small por-
tionofMn2+ tooxidizetoMn3+.Thissynergistic relationship
betweenMn2+ and Mn3+,resultsincontinuousredoxcycling
[69].These ﬁndings lead usto hypothesize thatif theanimals
a r ee x p o s e dt ot h em i x t u r eo fM n 2+/Mn3+,i tw o u l db e
possible to ﬁnd cell and behavioral alterations resembling
those found in PD.
Since it has been postulated that Mn3+ is more potent in
producing oxidative stress and Mn2+ needs the presence of
Mn3+ to reach oxidation and that there is a synergy between
the two Mn states, the current study investigates the eﬀects
of Mn2+/Mn3+ mixture inhalation on mice to obtain a novel
animal model of PD inducing bilateral and progressive cell
deathintheSNcandcorrelatingthosealterationswithmotor
disturbances. As a next step, we sought to determine if after
Mn inhalation the movement alterations improve with l-
DOPAtreatmentinordertoensurethatthealterationsorigin
is dopaminergic.Parkinson’s Disease 3
2.ExperimentalProcedures
Fourty-ﬁve CD-1 male mice weighing 33 ± 2gwere indi-
vidually housed in hanging plastic cages under controlled
light conditions (12h light/h dark regime) and fed with
Purina Rodent Chow and water ad libitum.B o d yw e i g h t
was recorded daily. The experimental protocol was conduced
in accordance with the Animal Act of 1986 for Scientiﬁc
Procedures. All eﬀorts were made to minimize the number
of animals used and their suﬀering.
2.1. Motor Behavior. Prior to Mn inhalation, all the animals
were trained in the reaching task and beam-walking test
to evaluate motor performance. Training and testing were
performed during the lighted portion of the cycle, at the
same hour every time. For the reaching task mice were
food deprived to 90% of normal body weight and received
measured amounts of food once a day to maintain body
weight and deprivation state. The motor behavior tests were
performed during the days the animals did not inhale. Each
mouse was tested once a week, a diﬀerent day for each test.
Two observers blind to the mice exposed or control status
perform all behavioral assessments.
2.2. Single-Pellet Reaching Task. The plexiglas reaching box
was 19.5cm long, 8cm wide, and 20cm high. A 1-cm wide
vertical slit ran up the front of the box. A 0.2cm thick
plastic shelf (8.3cm long and 3.8cm wide) was mounted
1.1cm from the ﬂoor on the front of the box. Before
training, animals were food deprived for 24hr. Afterward,
they received a restricted diet of ∼10gm/kg body weight
adjusted to keep their weight constant. Twenty milligram
food pellets were placed in indentations spaced 1cm away
from the slit and centered on its edges. Animals were
habituated for 1 week by placing them in the cages for 10
minutes. Pellets were initially available on the cage ﬂoor and
within tongue distance on the shelf. Pellets were gradually
removed from the ﬂoor and placed farther away on the
shelf (1cm) until the mouse were forced to reach to retrieve
the food. As the animal pronates the paw medially, this
placement allows the mouse to obtain the pellet with a paw
and not with the tongue. Mice were individually trained
and allowed to reach with their preferred forelimb for food
pellets [70]. Each animal reached for 20 pellets each day
during the testing period. If an animal reached through the
slot and obtained a food pellet, the reach was scored as a
success. If an animal knocked the food away or dropped the
food after grasping it, the reach was scored as a miss [71].
Qualitative assessment consisted in analyzing the “reaching
performance,” the postural shift and impairments in limb
extension, aim, and supination-pronation of the paw during
grasping, and release of the pellet into the mouth.
2.3. Beam Walking Test. The additional test to measure
motor coordination of mice was assessed by measuring the
ability of the animals to traverse a narrow beam (3mm)
to reach an enclosed safety platform [72]. The apparatus is
constructed by elevating surface of a 10 × 100cm × 3mm
wooden beam 75cm above the ﬂoor with wooden supports
with 15◦ inclination. A goal box is located at one end of the
beam. During training, animals were placed at the beginning
of the beam with no inclination and they were trained over
4 days (4 trials per day). Once the animals crossed the beam
in a 20 seconds interval, they received two more consecutive
trials with the inclined beam. Animals were allowed up to 60
sec to traverse the beam. The latency to traverse beam was
recorded for each trial.
2.4. Video Recording. Performance during single pellet
reaching and beam walking tests was video recorded using
a Sony camcorder (1000th of a second shutter speed). The
camera was positioned orthogonally to the reaching box
such that the animal behavior was ﬁlmed from the front.
Representative still frames were captured from digital video
recordings with the video editing software Final Cut Pro.
Pictures were cropped and adjusted for color and brightness
contrast in AdobePhotoshop V.11.0.2butwere notalteredin
any other way.
Neurological Evaluation. Tremor and bradykinesia (slowed
ability to start and continue movements and impaired ability
to adjust body’s position) were evaluated by inspection
of Mn-exposed compared with control mice during the
performance of the two tests.
2.5. Manganese Inhalation
2.5.1. Pilot Study. A pilot study was performed (5 control
and 5 Mn exposure mice) with 0.02 and 0.03M Manganese
chloride (MnCl2) and 0.01 and 0.02M Manganese acetate
[Mn(OAc)3](SigmaChemicalC oM e xic o),andaft er6,8,10,
and 12 inhalations by light microscopy, some changes were
observed in SNc tyroxine hidroxylase (TH) immunoreactive
neurons. However, the loss of TH-immunostained cells
were not enough to observe behavioral alterations (data
not shown). Thus, higher doses were used; the mixture of
0.04M MnCl2 and 0.02M Mn(OAc)3,a n dk n o w i n gt h a t
the half-life of Mn is about 30–48h and scarce information
is available about inhalation, we planned a twice a week
exposure protocol.
Inhalations were performed as described by Avila-Costa
et al. [73]. Twenty animals were placed in an acrylic cham-
ber inhaling 0.04M MnCl2 and 0.02M Mn(OAc)3 (Sigma
Aldrich,Co.Mexico)1htwiceaweekforﬁvemonths.Fifteen
control mice inhaled only the vehicle—deionized water—
for the same period. Inhalations were performed in closed
acrylic boxes (35cm wide × 44cm long and 20cm high)
connected to an ultranebulizer (Shinmed, Taiwan), with
10l/min continuous ﬂux. The ultranebulizer is designed to
produce droplets in a 0.5–5μm range. A trap for the vapor
was located in the opposite side with a solution of sodium
bicarbonate to precipitate the remaining metal. During
exposures, animals were continuously visually monitored for
respiration rate, depth, and regularity. The exposure system
was continuously monitored for temperature, oxygen level,
and Mn concentration.4 Parkinson’s Disease
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Figure 1: Decrease of dopamine content in the striatum after
5 months of Mn inhalation compared to controls. Contents are
expressed as percentages, which were in pg/micro gram of protein
(∗P<. 001 versus control group by one-way ANOVA with post-hoc
comparisons).
After 5 months (40 inhalations), when important motor
alterationswere observed,20micewere sacriﬁced (10control
and 10 Mn-exposed), anesthetized with sodium pentobar-
bital lethal dose, and perfused via aorta with phosphate
buﬀer saline (0.1M p.H. 7.4) containing 2% glutaraldehyde
and 2% paraformaldehyde. The brain was removed and
placed in ﬁxative solution for 2hr and processed for TH
inmunocytochemistry (5 control and 5 Mn-exposed brains).
Afterwards, the remaining mice continued inhaling Mn.
Five were orally treated with 7.5mg/kg l-DOPA (Sinemet
[Carbidopa-l-DOPA 25/250]) daily for two months, 5 were
kept for the same time without treatment, and 5 control
were kept for the same time and then sacriﬁced for further
analysis; the motor performance was evaluated weekly.
2.6. Immunocytochemistry. Coronal sections (50μm) were
obtained on a vibrating microtome through the mesen-
cephalon for immunocytochemistry. Tyrosine hydroxilase
(ChemiconInternational, Inc. CA, USA, 1:1000) immunos-
taining with the ABC detection method (Vector Lab MI,
USA) was performed for light microscopic analysis. The
analysis was conducted with a computer-assisted system
(Image-Pro Plus, Media Cybernetics, L.P. DelMar, CA,USA)
connected by a CCD camera to Optiphot 2 microscope
(Nikon, Japan). The number of TH-positive neurons was
countedin 1500μm2 from 14 mesencephalic sections of each
animal, the cell count included SNc and ventral tegmental
area (VTA) [73].
2.7. Dopamine Concentrations. Striatal dopamine contents
were obtained after 5 months of Mn inhalation as described
elsewhere [74]. Brieﬂy, 5 control and 5 Mn-exposed mice
were anesthetized and decapitated, and using a stereoscopic
microscope the striatum was dissected. The tissue was
homogenized in perchloric acid utilizing 100μlp e rb r a i n .
Homogenates were centrifuged (300PSI, 2min, airfuge cen-
trifuge,Beckman;Fullerton,CA,USA),and thesupernatants
were ﬁltered (0.22-μm membranes, Millipore; Bedford,
MA, USA). The pellets were resuspended (120μlo f0 . 1 M
NaOH) and used for protein determination as reported by
Bradford[75].Dopaminecontentin10μlofsupernatantwas
determined using a reverse phase HPLC system coupled to
an electrochemical detector (BAS; West Lafayette, IN, USA).
Chromatograms were analyzed using the Peak II integration
software (SRI Instruments; Torrance, CA, USA). The DA
content was expressed as pg/μgp r o t e i n .
2.8. Mn Concentrations. The concentrations of Mn in the
chamberwere quantiﬁedasfollows. Aﬁlterwaspositioned at
the outlet of the ultranebulizer during the whole inhalation
time at a ﬂow rate of 10l/min. After each exposure, the ﬁlter
was removed and weighed; the element was quantiﬁed using
a graphite furnace atomic absorption spectrometer (Perkin
Elmer Mod. 3110, CT, USA). Six ﬁlters for each inhalation
were evaluated[76].Mn contentinserumwas also measured
by graphite furnace atomic absorption spectrometry at the
end of the experiment.
2.9. Statistical Analysis. One-way ANOVA was used to ana-
lyze the number of TH-immunopositive cells and behavioral
data. Group diﬀerences were considered statistically signif-
icant at P<. 05. When appropriate, post-hoc comparisons
were made with the Tukey test. All analyses were conducted
with SigmaPlot 11 (SYSTAT Software).
3.Results
After 7 months of exposure neither clinical alterations nor
signiﬁcant weight changes were detected in the exposed
animals compared with controls.
3.1. Manganese Concentrations. The average Mn concentra-
tionmeasuredintheﬁltersofthechamberwasof2676μg/m3
duringthe wholeexperiment. The averageMn concentration
in serum of exposed animals was of 30 ± 5μg/l; control mice
serum concentration of Mn was of 0.05–0.12μg/l.
Figure 1 shows the change in dopamine content deter-
mined in the striatum after 5 months of Mn inhalation
compared to controls. The average content in the control
mice was 96.545 ± 4.8820 and 28.008 ± 12.4500pg/μgo f
protein for Mn-exposed mice; hence, dopamine content
declines 71%.
3.2. Single-Pellet Reaching Task. The task involves execution
of a complex motor sequence, starting with sniﬃng a food
pellet at the front of the reaching chamber, lifting the arm,
adjusting posture to project the arm through a narrow slot
toward the pellet, and grasping the target (Figure 2).
Animals were presented with 20 food pellets. Figure 3
shows the results of successful reaches over the course of the
experiment. Repeated-measures ANOVA conﬁrmed a signif-
icant eﬀect of Mn-exposed group since 8 Mn-inhalations
(P<. 001). All animals were comparable in their ability to
retrieve pellets before Mn inhalation, but the Mn exposureParkinson’s Disease 5
Figure 2: Representative stillframes ofa control mousecaptured during limbtransportandlimbwithdrawal.Thecontrolanimalsadvanced
their forelimb through the slot and extended their digits, and they also supinated their paw to present the food to the mouth and extended
their digits to release the food into the mouth (see text for detailed description.)
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Figure 3: Reaching success (number of pellets obtained out of 20;
mean ± SEM) by control, Mn exposed and Mn exposed + l-DOPA
treatment mice in the single-pellet task before and after inhalation
and after l-DOPA treatment. Note that the Mn-exposed group is
impaired since 8 week and the l-DOPA treatment fully reverses the
alterations (∗P<. 001 versus control group; P<. 001 between
l-DOPA treatment group versus Mn exposed group).
resulted in a marked impairment in both number of suc-
cessful retrievals (P<. 001) and accuracy; however, when l-
DOPA treatment starts the mice improve their performance
when comparingtothenontreated ones,resembling thecon-
trol mice execution (P<. 001). Control animals remained
consistent throughout the duration of the experiment and
performed signiﬁcantly better than Mn-exposed animals at
all time points (Figures 2 and 3).
Qualitative assessment resulted in a postural shift and
impairments in limb extension (resulting in many shortened
reaches), aim, and supination-pronation of the paw during
grasping and release of the pellet into the mouth (Figures
4(a)–4(d)). Mice displayed abnormal movements when
retrieving the pellet after Mn exposure. The paw is often
fully pronated and moves eitherlaterally (from the side) over
the pellet (Figures 4(b) and 4(c)), or the mouse slaps at the
pellet from above. Several animals from Mn-exposed group
exhibited such motor abnormalities that persisted for the
duration of the experiment.
T h eM n - e x p o s e dm i c ea r eo f t e nu n a b l et op r o p e r l yc l o s e
the digits around the pellet and drag it to the slot without
lifting the paw. Mice also fail to supinate the paw completely
and place the snout into the slot to retrieve the pellet with
the tongue. When the paw is withdrawn through the slot,
Mn mice frequently rotate the body and “chase” the pellet
with the snout instead of opening the digits and placing the
pelletintothemouth.Thenonreaching limbisseldomraised
for support when retrieving the pellet. Post-hoc tests on the
group eﬀect indicated that at more Mn exposure success
scores were signiﬁcantly poorer (Figure 3). These conditions
remarkably improve with l-DOPA treatment (Figures 4(e)–
4(h)); the treated mice adjust their posture and project the
arm toward the pellet, supinate and pronate the paw to
obtain the pellet, close their digits, and drag the food to the
snout; their motor performance was comparable to control
mice (Figure 3).
3.3. Beam-Walking Test. We further tested Mn-exposed mice
for possible alterations in motor activities using a beam
traversaltask.OnthelastdayoftestingbeforeMninhalation,
there was no signiﬁcant diﬀerence between the latencies
in completing the test for the controls (7.2 ± 6.9sec)
and the Mn-treated subjects (7.8 ± 3.1sec) (ANOVA test;
P>. 001). Throughout the course of the experiment, none
of the subjects fell from the beam.
Figure 5 illustrates the mean numbers of total time to
cross the beam. Mn-exposed mice were observed to have
a signiﬁcant decrease in the duration to cross the beam
after 2,4,6, and 8 Mn-inhalations suggesting hyperactivity;
afterwards have a signiﬁcant increase in the time to cross and
a signiﬁcant potentiation of freeze time (data not shown),
compared with control mice. In addition, animals were
also noted to exhibit hind-limb weakness, delayed motor
initiative (akinesia), postural instability, and action tremor.
l-DOPA treatment reverted these motor alterations.
3.4. TH-Immunocytochemistry
3.4.1.PilotStudy. Themeannumber ofTH-positiveneurons
on the control SNc was 145 neurons (Figures 6 and 7(a)).
In the 0.02M MnCl2-inhaled animals, TH-positive neurons
in the SNc were reduced by 4.8–33% (138 and 98 neurons6 Parkinson’s Disease
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 4: Representative still frames of a Mn-inhaled mouse (a–d) and Mn-inhaled mouse + l-DOPA treatment (e–h). In frames (a)–(d),
the mouse showed impairments using extreme postural adjustments advancing the limb diagonally through the slot making many short
attempts rather than aligning the limb with the midline of the body. The digits are concurrently adducted. The paw comes in from the side
orslapslaterally,anddigitsdonotcontactthefoodpellet. Themouseisdraggingitslimbthrough theslotanddroppingthepellet to theﬂoor
cage chasing the food with the tongue rather than fully pronating the paw and supinating it to present the food to the mouth. In contrast, in
frames (e)–(h), the eﬀect of l-DOPA treatment is evident, and the mouse adjusts its posture, directs the arm to the food pellet, and closes
its digits to obtain it correctly.
resp. after 6 and 12 inhalations (Figures 6(a) and 7(b)); in
the 0.03M MnCl2-inhaled mice, TH-positive neurons in the
SNcwere reduced by 11.03–38.6%(129and 87 neurons resp.
after 6 and 12 inhalations (Figures 6(c) and 7(c)); in the
0.01M Mn(OAc)3-inhaled mice the reduction was from 20
to 44.8% (116 neurons after 6 inhalations and 80 neurons
after 12 inhalations (Figures 6(b) and 7(d)), and in the
0.02M Mn(OAc)3-inhaled mice the reduction was from 37.9
to 55.1% (90 neurons after 6 inhalations and 65 neurons
after 12 inhalations (Figures 6(d) and 7(e))). Despite these
reduction, after 10 inhalations in both cases the neuronal
loss reached a plateau and there were no evident behavioral
alterations. Hence, we decided to use higher doses and mix
both compounds; afterwards we found glaring cell reduction
(Figure 7(f)) and motor alterations described above.
3.5. MnCl2/Mn(OAc)3 Mixture. After 40 MnCl2/Mn(OAc)3-
inhalations, a signiﬁcant loss of the TH-positive neurons in
the SNc was observed (67.58%) compared with the control
group.However,thenumberandintegrityoftheTH-positive
neurons in the VTA were not signiﬁcantly aﬀected by Mn-
inhalation (7.6%) (Figures 8 and 9).
4.Discussion
This study examined the premise that exposure to MnCl2
/Mn(OAc)3, when combined, produces additive or even
synergistic eﬀects by impacting the DA nigrostriatal system
byreducingTHcellcountsintheSNcbutnotintheVTAand
decreasing dopamine striatal concentrations. We found con-
siderablehyperactivity immediately after the ﬁrst inhalations
(2–8 inhalations) and afterwards, evident reduction and
alterations in locomotor activity, and the motor alterations
improve drastically after l-DOPA treatment.
4.1. Motor Behavior Alterations
4.1.1. Single-Pellet Reaching Task. The single-pellet task
examined both gross ability to retrieve pellets and reaching
accuracy, which is more sensitive to subtle impairments and
compensatory reaching strategies that may not be detected
by other motor tests [77].
Detailed analyses of skilled limb movements, such as the
reach-to-grasp movement, show very similar motor com-
ponents in humans and in rodents [78, 79]. An analysis of
the movements used by the rodents indicates that a reach
consists of postural adjustments that result in the body being
supportedbythediagonalcoupletofthehindlimbipsilateral
to the reaching forelimb and its opposite forelimb. This
postural strategy allows the body to shift forward and back-
ward and so aid limb advancement and withdrawal. The
reaching movement itself consists of a number of movement
subcomponents that include aiming the limb, pronating
the paw over the food in order to grasp, and supinatingParkinson’s Disease 7
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the paw as it is withdrawn so that the food can be presented
to the mouth. Humans with PD are often described as
having poor manual dexterity that worsens as the disease
progresses [80, 81]. They experience diﬃculties executing
tasks requiring unilateral arm movements, bilateral arm
movements, and sequential and alternating limb movements
[79]. Movements by more distal body segments are more
aﬀected than movements by more proximal body segments.
After Mn exposure, mice commonly drag the pellet
across the ledge without lifting the paw and either place the
snout into the slot to retrieve the pellet with the tongue or
rotate the body and “chase” the pellet with the snout when
the pellet is withdrawn through the slot into the box. Those
alterations could include damage to regions of the basal
ganglia responsible for grasping movements [82].
With the results presented here, we conﬁrm that bilateral
DA-deﬁcient mice have impairment in their success in
retrieving food pellets. The video analysis of the reaching
movements indicated that the Mn-exposed mice displayed
impairment insupinating thepaw tobring foodtothe snout.
Rather than supinating, the paw was adducted across the
snout so that the mouth contacted the upper surface of the
paw. Food was lost because the paw is often fully pronated
and moves either laterally over the pellet or the mouse slaps
at the pellet from above. On the other hand, mice retained
the ability to align and aim their limb to initiate a reach and
toadvance thelimb tothefood. Thus, thesensory and motor
mechanisms underlyingthesemovementsmustinvolvesome
motor cortical areas, which we assume intact; thus, in order
to conﬁrm that the motor alterations are due to basal ganglia
damage, we utilized the beam walking test which is sensitive
to impairments in the nigrostriatal pathway [83].
4.1.2. Beam Walking Test. The motor function impairments
observedonthebeamwalkingtaskarecomparablewithpub-
lished ﬁndings in which C57 BL6/J mice treated with acute
and subchronic dosing regimens of MPTP and were reported
to display impairments in limb coordination, stride length,
andmotorfunction,at1-2weekspost-MPTP administration
[84,85].Inaddition,theMPTP-induced increaseinduration
to traverse the beam also concords with published studies
in which transgenic mouse models of PD were signiﬁcantly
slower in traversing a narrow, raised beam than wild-type
control animals [86]. Qualitative analysis showed that Mn-
exposed animals exhibit hind-limb weakness, delayed motor
initiative (akinesia), postural instability, freezing behavior,
and action tremor. Regarding these alterations, Autissier et
al. [21] reported that mice subchronically exposed to Mn
by intragastric gavage showed hypoactivity, this change was
associated with a drop in striatal DA of 50%; Eriksson et al.
[14] found that about 5 months after the start of the Mn
exposure the animals became hypoactive with an unsteady
gait and subsequently an action tremor. The animals lost
power in both upper and lower limbs, and the movements
of the paws were very clumsy. Moreover, Mn3+ injected into
the rat SNc decreased spontaneous motor activity, rearing
behavior, and acquisition of an avoidance response [38–40].
Regarding the hyperactivity observed after 2–8 Mn-
inhalations (Figure 5), it has been reported that in early
stages of Mn exposure the subjects manifest psychomotor
e x c i t e m e n t ,i r r i t a b i l i t y ,a n dc o m p u l s i v eb e h a v i o r[ 14, 42].
Nachtman et al. [87] indicate that acute exposure to Mn
is associated with an increase in DA neurotransmission,
which is also manifested as hyperactivity. Nevertheless, long-
term exposure results in a loss of DA in the brain, and
the concomitant neuronal cell damage could be expressed
as a decrease in motor activity. Shukla and Singhal [88]
reported that acute exposure to Mn2+ causes hyperactivity
accompanied by elevated brain levels of catecholamines
and their metabolites. Moreover, Tomas-Camardiel et al.
[57] reported that experimental rats were signiﬁcantly more
active than control animals in the empty open ﬁeld after Mn
exposure.
It has been mentioned that rats with bilateral 6-OHDA
lesions have postural abnormalities at rest and a reduced
capacity to maintain balance after challenges with destabi-
lizing forces. Likewise, spontaneous movements are greatly
reduced [89].
Reports of parkinsonian-like tremor have been scarce in
studies of 6-OHDA-lesioned rats [90, 91]; however, Schallert
et al. [92] have observed occasional resting tremor in the
wrist and the paw of rats with severe DA depletion (either
bilateral or unilateral). This tremor can be seen only when
the forelimb is positioned oﬀ the ﬂoor in a nonweight-
bearing posture [92]. As it has been reported, rats with
bilateral6-OHDAlesionsshowalloftheessentialelementsof
parkinsonian motor syndromes. However, animals lesioned
bilaterally with 6-OHDA is not a common model, as they8 Parkinson’s Disease
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Figure 6: Pilot study. Number of SNc TH+-immunostained neurons from control and exposed mice after diﬀerent times of 0.02M MnCl2
(a) and 0.03M MnCl2 (c) inhalations and after diﬀerent times of 0.01M Mn(OAc)3 (b) and 0.02M Mn(OAc)3 (d) inhalations.The data are
presented as the mean ± standard error (SE) (∗P<. 05 one-way ANOVA).
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Figure 7:Pilotstudy. Representative coronalTH-immunostainedsections throughthe SNandVTAofcontrolandexposed miceto diﬀerent
Mn concentrations and compounds (4x).Parkinson’s Disease 9
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Figure 8: TH-immunoreactive cell counts from the Substantia
Nigracompacta(SNc)andVentralTegmentalArea (VTA).Thedata
are presented as the mean ± SE. A statistically signiﬁcant decrease
in TH-immunoreactive cells was detected in the SNc (∗P<. 05
ANOVA test) of Mn-exposed mice compared to controls with no
diﬀerence in the VTA.
require intensive nursing care [93]. So, rats with unilateral
6-OHDA lesion of the nigrostriatal dopamine pathway are
the most widely used animal model of PD. However, this
model does not mimic all the clinical and pathological
features characteristic of PD. Furthermore, the acute nature
of the experimental model diﬀers from the progressive
degeneration of the dopaminergic nigral neurons in PD.
4.1.3. TH-Immunocytochemistry. Contrary to previous re-
ports [12, 14, 18, 23, 42–44, 57, 58], we found an important
loss of TH-positive neurons as shown in Figures 8 and 9,
exhibiting a pattern very similar to that observed in PD
patients; according to our ﬁndings, some authors have been
reported neurochemical changes in human and animal Mn
intoxication including the reduction in DA levels and TH+
immunoreactivity in the caudate nucleus, putamen, and SN
[7, 8, 21, 27, 54–56]. In this way, it has been hypothesized
that Mn interacts with catechols speciﬁc to dopaminergic
neurons so as to rapidly deplete them and render such cells
no longer viable [34, 66].
The controversy found here about the loss of TH cell
count, decreased DA striatal concentrations, and the behav-
ioral alterations, may be due to the fact that we included the
mixture of MnCl2/Mn(OAc)3.A c c o r d i n gt os o m ea u t h o r s ,
the pro-oxidant activity of Mn2+ is dependent on trace
amounts of Mn3+, which may facilitate a small portion
of Mn2+ to oxidize to Mn3+. This synergistic relationship
between Mn2+ and Mn3+ results in continuous redox cycling
[69]. It seems that Mn2+ fails to induce oxidative eﬀects;
however, transition of Mn2+ t ot h et r i v a l e n ts t a t el e a d s
to an increased oxidant capacity of the metal which may
result in the production of reactive oxygen species, lipid
peroxidation, and cell membrane damage [59], and may in
turn attack catecholamine neurotransmitters [40, 66]; thus,
the inherent convertion of Mn2+ to Mn3+ and the presence
ofmoreMn3+ couldinducemore reactiveoxygenspeciesand
mitochondrial disfunction [94, 95] manifested as the evident
DA cell loss and the motor disturbances found here.
Several explanations have been proposed to elucidate the
vulnerability of dopamine to Mn, such as the impairment
of cellular antioxidant defenses by the accumulation of
the metal, and the disruption of mitochondrial oxidative
energy metabolism [94]. This has led to the conclusion that
excessive levels of brain Mn induce oxidativestress leading to
neurodegeneration [69].
It has been mentioned that the brain is an important
target of attack for transition metal ions, such as Mn, due
to its great catecholamine concentration and the high speed
ofoxidative metabolism catalyzedby these metals [96]. DAis
oxidized to aminochrome by reducing Mn3+ to Mn2+ [60],
which may react with O2−• radicals to generate hydrogen
peroxide and more Mn3+ [66].
According to HaMai and Bondy [69], loss of the
dopaminergic neurons in the nigrostriatal pathway of the
basal ganglia, which are inhibitory, leads to heightened
activity of neurons in the GP. Since GP eﬀerences are also
inhibitory, the sum of increased suppression of motor func-
tions produces the symptoms characteristic of Mn-related
parkinsonism. More speciﬁcally, rigidity and bradykinesia
arise from the degeneration of neurons in the SNc, which
project to the striatum. The Mn-induced alterationsare focal
to both pre- and postsynaptic terminals of the dopaminergic
nigrostriatal pathway [52]. The subcellular localization of
Mn occurs in the mitochondria, speciﬁcally inhibiting
complex I, since Mn has a high aﬃnity for the inner
mitochondrial membrane [32, 54, 68, 95]. Salient features of
the brain regions susceptible to Mn-provoked injury include
their intense oxidative metabolism, major DA content, and
high content of nonheme iron [32, 59, 69]. This raises
the possibility that the mechanisms of Mn neurotoxicity
relate to its potential for oxidative injury and promotion of
DA auto-oxidation [36, 66]. The mechanisms by which the
common neurotoxinskilldopaminergicneuronsalsoinvolve
mitochondrial dysfunction and oxidative damage. 6-OHDA
is taken up by DAT, and it then generates free radicals [97].
MPTP is converted by monoamine oxidase B to 1-methyl-
4-phenylpyridinium (MPP+). MPP+ is taken up by DAT
and can then be accumulated by mitochondria, leading to
complex I inhibition and the generation of free radicals [98].
In this way, Hirata et al. [99] suggest that the mechanisms by
which Mn produces dysfunction of the nervous system are
similar to those of MPTP.
It is also worth noting that, in this study, although Mn-
inhalation caused signiﬁcant damage to dopaminergic neu-
rons in the SNc, the dopaminergic neurons in VTA did not
appear to be aﬀected. It is not clear whether this suggests
anyselectivityinMn-inducedtoxicitybetweendopaminergic
neurons in the SNc and those in the VTA; however, it has
been mentioned that Mn enters the neurons possibly via
DAT [29–31]; DAT has been shown to be involved in
the selective neurotoxicity of MPTP [98], 6-OHDA [97],
and that of Thiruchelvam et al. [27], where SNc is more10 Parkinson’s Disease
Control
(a)
MnCl2/Mn(OAc)3
(b)
(c) (d)
(e) (f)
Figure 9: Representative TH-immunostained from coronal section containing the SN and VTA of control and Mn-exposed mice. Note the
relative sparing in the ventral tegmental area and profound cell loss at all levels of SNc in the Mn-exposed group (upper panel 4x, middle
panel 10,000x, and lower panel 40,000x).
susceptible than VTA. It seems that dopaminergic cells of
the SNc and the VTA display diﬀerences in their topography,
biochemistry, and susceptibility to pathological processes
[100], VTA express lower levels of DAT than the middle and
medial SNc[98,101];th us ,itispos s ibleth atM nr eac h esSNc
dopaminergic cells via the large amounts of DAT found on
those neurons; however, additional studies are needed.
Currently available animal models of PD have con-
tributedgreatly toour understanding ofboth thepathophys-
iologyandpotentialneuroprotectivetherapeuticsforPD,but
as yet we do not have the optimal model. At present, MPTP
neurotoxicity is the best available animal model from several
standpoints, and it has been extremely valuable in testing
neuroprotective and neurorestorative strategies. Neverthe-
less, the disadvantages of theMPTP model are: acutedamage
of the dopaminergic system and nonprogressive and rare
generation of inclusion bodies [102]. Both, 6-OHDA and
MPTP models diﬀersigniﬁcantly fromthe slowly progressive
pathology of human PD [4]. In addition, genetic mouse
models of PD have previously been observed to repeat some
aspects of the disease in the absence of substantial neuronal
loss in the aﬀected brain subregions [103]. Transgenic mice
overexpressing wild-type and FPD-linked mutant human
alfa-synuclein exhibit motor deﬁcits in the absence of loss of
DA neurons [4, 104].
The signiﬁcant decrease (67.58%) in the number of
SNc TH-immunopositive neurons after MnCl2/Mn(OAc)3
inhalation and the evident reduction of striatal dopamine
concentrations reported here demonstrates a glaring reduc-
tion of this chatecolamine content (71%). Hence, we assume
that the alterations are due to dopaminergic loss since
l-DOPA-treated mice almost completely improved their
motor performance.
It has been reported that Mn eﬀects involve the GP [43,
44, 105]; however, with these results we can assure that the
MnCl2/Mn(OAc)3 mixture also jeopardizes the nigrostriatal
pathway. In this study, we have demonstrated that l-DOPA
treatment signiﬁcantly improves themotoralterations found
after Mn exposure, suggesting that these motor disturbances
are of dopaminergic origin. Moreover, Mn mixture inhala-
tion was extensive enough to induce substantial and stable
deﬁcits in spontaneous sensorimotor behaviors including
tremor, posture instability, slowed movement, and rigidity;
and in contrast to the complete nigrostriatal bundle lesion
produced by other PD models such as 6-OHDA, which is
the most commonly used model in functional experimentalParkinson’s Disease 11
studies,the Mnmixture inhalationleavesaconsiderablepor-
tion of the nigrostriatal projection intact. As in early stages
of PD, the presence of an intact, functioning subportion of
the nigrostriatal system could allow l-DOPA treatment to be
eﬃcient.
In summary, the results from this study suggest that
the motor alterations induced by the inhalation of the
combinationofMnCl2/Mn(OAc)3 are related tonigrostriatal
dopaminergic function, providing new light on the under-
standing of Mn neurotoxicity as a suitable PD experimental
model.
In conclusion the data described in the present study
provides further evidence that functional deﬁcits following
Mn exposure in mice can be quantiﬁed and are related
to nigrostriatal DA function. The motor and immunocyto-
chemical discrepancies reported here are probably due to the
combinationofMnCl2/Mn(OAc)3,since ithasbeenreported
that Mn3+ is more potent in producing oxidative stress and
cell damage and Mn2+ needs the presence of Mn3+ to reach
oxidation and that there is a synergy between the two Mn
states, and so far, there is no research that has included
this mixture. Therefore, we consider that the inhalation
of MnCl2/Mn(OAc)3 mixture could be an appropriate PD
model.
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